Two HIV competitors: lencapravir and Cabo/Rilpi

Two HIV competitors: lencapravir and Cabo/Rilpi

Thanks much to viridi for this info. Maybe someone can help me out with questions I have.

Lencapravir is a capsid assembly/disassembly blocker in phase 1 human trials from Gilead which is dosed once every six months.

Gilead put up a poster presentationon lencapravir this past AIDS:2020 Virtual July 6-10.

I can't find the poster presentation. Anyone have access?

Gilead press release from July 2 says lencapravir is used in conjunction with arntiviras so I am not sure if lencapravir is intended as a montherapy. Also not sure if lencapravir will reduce HAART side effects. Also not sure about lencapravir side effects. Probably all are addressed in the recent AIDS:2020 Virtual poster presentation but I cant find that poster presentation.

Next up is Roche's Cabotegravir/Riolivirine. Cabo/Rilpi is a monthly or every two months injectable that is essentially the same as standard HAART, I think. So no reduction in HAART side effects, I think.

For all new drugs patient compliance is a key issue. Both lemapravir and cabo/rilpi have potential compliance advantages vs. daily HAART dosing and weekly leronlimab dosing.

However, a missed leronlimab dose may be of less importance than a missed lencapravir or cabo/rilpi dose.